studies

la/mBC - HR-positive - 2nd line (L2), ribociclib based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsMONALEESA-3, 2018 0.72 [0.57; 0.91] 0.72[0.57; 0.91]MONALEESA-3, 201810%726NAnot evaluable deaths (OS) (extension)detailed resultsMONALEESA-3, 2018 0.73 [0.59; 0.90] 0.73[0.59; 0.90]MONALEESA-3, 201810%726NAnot evaluable progression or deaths (PFS)detailed resultsMONALEESA-3, 2018 0.59 [0.48; 0.73] MONALEESA-7, 2018 0.55 [0.44; 0.69] 0.57[0.49; 0.67]MONALEESA-3, 2018, MONALEESA-7, 201820%1,398lownot evaluable CBRdetailed resultsMONALEESA-3, 2018 1.40 [1.01; 1.94] MONALEESA-7, 2018 1.64 [1.16; 2.33] 1.51[1.19; 1.91]MONALEESA-3, 2018, MONALEESA-7, 201820%1,398lownot evaluable objective responses (ORR)detailed resultsMONALEESA-3, 2018 1.75 [1.22; 2.52] MONALEESA-7, 2018 1.64 [1.19; 2.26] 1.69[1.33; 2.15]MONALEESA-3, 2018, MONALEESA-7, 201820%1,398lownot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-18 08:58 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1379,1403,1381,1380

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons